[go: up one dir, main page]

BR9806210A - Processos de contracepção masculina e para terapia de substituição de androgênio, contraceptivo masculino, e, forma de dosagem para a terapia de substituição de androgênio. - Google Patents

Processos de contracepção masculina e para terapia de substituição de androgênio, contraceptivo masculino, e, forma de dosagem para a terapia de substituição de androgênio.

Info

Publication number
BR9806210A
BR9806210A BR9806210-7A BR9806210A BR9806210A BR 9806210 A BR9806210 A BR 9806210A BR 9806210 A BR9806210 A BR 9806210A BR 9806210 A BR9806210 A BR 9806210A
Authority
BR
Brazil
Prior art keywords
processes
replacement therapy
male
androgen replacement
dosage form
Prior art date
Application number
BR9806210-7A
Other languages
English (en)
Inventor
Alfred J Moo-Young
Original Assignee
Population Council Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Population Council Inc filed Critical Population Council Inc
Publication of BR9806210A publication Critical patent/BR9806210A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

"PROCESSOS DE CONTRACEPçãO MASCULINA E PARA TERAPIA DE SUBSTITUIçãO DE ANDROGêNIO, CONTRACEPTIVO MASCULINO, E, FORMA DE DOSAGEM PARA A TERAPIA DE SUBSTITUIçãO DE ANDROGêNIO". A presente invenção diz respeito a processos para prover a contracepção masculina usando -se um androgênio especificado sem a necessidade de um agente esterilizante separado. A invenção também descreve processos para substituição de androgênio não-contraceptivo e dispositivos úteis para realizar ambos os processos.
BR9806210-7A 1997-09-17 1998-09-17 Processos de contracepção masculina e para terapia de substituição de androgênio, contraceptivo masculino, e, forma de dosagem para a terapia de substituição de androgênio. BR9806210A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5930097P 1997-09-17 1997-09-17
US6296297P 1997-10-10 1997-10-10
US09/154,283 US6767902B2 (en) 1997-09-17 1998-09-16 Androgen as a male contraceptive and non-contraceptive androgen replacement
PCT/US1998/019402 WO1999013883A1 (en) 1997-09-17 1998-09-17 Androgen as a male contraceptive and non-contraceptive androgen replacement

Publications (1)

Publication Number Publication Date
BR9806210A true BR9806210A (pt) 2000-04-18

Family

ID=27369621

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806210-7A BR9806210A (pt) 1997-09-17 1998-09-17 Processos de contracepção masculina e para terapia de substituição de androgênio, contraceptivo masculino, e, forma de dosagem para a terapia de substituição de androgênio.

Country Status (6)

Country Link
US (2) US6767902B2 (pt)
EP (1) EP0966288A4 (pt)
JP (1) JP2001505589A (pt)
BR (1) BR9806210A (pt)
CA (1) CA2271657C (pt)
WO (1) WO1999013883A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10104327A1 (de) * 2001-01-24 2002-07-25 Schering Ag 11beta-Halogensteroide, deren Herstellung und Verwendung zur Herstellung von Arzneimitteln sowie 11beta-Halogensteroide enthaltende pharmazeutische Präparate
BR0313210A (pt) 2002-07-24 2005-06-28 Schering Ag Processos microbiológicos para a produção de 11alfa-hidróxi esteróides 7alfa-substituìdos
DE10233723A1 (de) * 2002-07-24 2004-02-12 Schering Ag Mikrobiologische Verfahren zur Herstellung von 7α-substituierten 11α-Hydroxysteroiden, daraus herstellbare 7α,17α-substituierte 11β-Halogensteroide, deren Herstellungsverfahren und Verwendung sowie pharmazeutische Präparate, die diese Verbindungen enthalten, sowie daraus herstellbare 7α-substituierte Estra-1,3,5(10)-triene
JO2492B1 (en) 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
US20070190067A1 (en) * 2006-02-01 2007-08-16 Savage Paul B Cationic Steroid Antimicrobial Compositions and Methods of Use
EP2688571A1 (en) 2011-03-22 2014-01-29 The Population Council, Inc. Myelin regeneration with androgens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177267A (en) 1963-12-09 1979-12-04 Crown Zellerbach Enhancing tissue penetration of physiologically active steroidal agents with DMSC
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4788218A (en) * 1984-05-21 1988-11-29 Sri International 17 a β-hydroxy-7 α-methyl-d-homo-19-norandrost-4,16-diene-3-one and the 17-esters thereof: methods of preparation and uses
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5342834A (en) 1989-04-07 1994-08-30 The Population Council, Inc. Method for androgen supplementation
EP0500287B1 (en) 1991-02-20 1995-04-26 Hitachi, Ltd. Catalyzer control apparatus
US5332576A (en) 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
CA2075517C (en) 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
ES2164286T3 (es) 1993-04-20 2002-02-16 Hexal Ag Emplasto con sustancias activas.
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5733565A (en) 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant

Also Published As

Publication number Publication date
CA2271657A1 (en) 1999-03-25
US6767902B2 (en) 2004-07-27
EP0966288A1 (en) 1999-12-29
EP0966288A4 (en) 2004-11-10
CA2271657C (en) 2007-08-07
WO1999013883A1 (en) 1999-03-25
JP2001505589A (ja) 2001-04-24
US20040132698A1 (en) 2004-07-08
US20020193359A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
DE60141145D1 (pt)
BR0016708A (pt) Forma de dosagem de droga baseada em hidrogel
BR9710198A (pt) Contraceptivo oral constituìdo por combinação farmacêutica de estrogênio-androgênio-progestina.
BR0113067A (pt) Forma de dosagem de drogas à base de hidrogel
BR9813982A (pt) Anticoncepcionais orais contendo antiestrogênio mais progestina
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
WO1995011013A3 (de) Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen
PT954314E (pt) Formas de dosagem farmaceutica para melhorar a disfuncao erectil masculina
ES2196079T3 (es) Procedimiento de fabricacion de unidades posologicas por medio de una granulacion por via humeda.
PT1079790E (pt) Utilizacao de composicoes microbicidas e espermicidas para inactivacao de virus sem envelope
PL327182A1 (en) Method of preventing conception among female mammals through combined application of gestagen and oestrogen and combination of active agent therefor
MX9701946A (es) Solucion oftalmica transportadora.
BR9712892A (pt) Dispositivo vaginal, e, processo para fornecer proteção contra gravidez ou doenca sexualmente transmissìvel, ou ambos.
IL166432A0 (en) Composition containing an androgenous 11?-halogen steroid and a progestational hormone and male contraceptive based on said composition
BR9806210A (pt) Processos de contracepção masculina e para terapia de substituição de androgênio, contraceptivo masculino, e, forma de dosagem para a terapia de substituição de androgênio.
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
DE69521122D1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
AP9801306A0 (en) Contraceptive release system with an antibacterial action and/or antiviral action.
BR9814136A (pt) Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto.
BG106534A (en) Oral solution containing galanthamine and a sweetening agent
MXPA01011296A (es) Composiciones contraceptivas que contienen derivados de indolina y agentes progestacionales.
NO975790L (no) Anvendelse av allylaminderivater slik som terbinafin, i fremstillingen av et medikament for behandling av helikobacterpylori-infeksjonsassosierte sykdommer
WO1996028154A3 (de) Verwendung von antiestrogenen zur männlichen fertilitätskontrolle
CO5070598A1 (es) Kit anticonceptivo que comprende medios para la administra- cion diaria de un agente anticonceptivo unico que es un com- puesto esteroide que combina las actividades progestagenica y estrogenica
EP0970697A4 (en) MATERIAL FOR CERVICAL MATURATION

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.